46 Result(s)
within
Jessica Zucman-Rossi
-
Article
Author Correction: A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
-
Article
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
An important challenge in the real-world management of patients with advanced clear-cell renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint blockade (ICB). Here we performed a ...
-
Article
Open AccessSingle-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma
Hepatoblastomas (HB) display heterogeneous cellular phenotypes that influence the clinical outcome, but the underlying mechanisms are poorly understood. Here, we use a single-cell multiomic strategy to unravel...
-
Article
Author Correction: Hepatocellular carcinoma
-
Article
Open AccessPreneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma
Pediatric liver tumors are very rare tumors with the most common diagnosis being hepatoblastoma. While hepatoblastomas are predominantly sporadic, around 15% of cases develop as part of predisposition syndrome...
-
Article
Benign liver tumours: understanding molecular physiology to adapt clinical management
Improvements in understanding the pathophysiology of the different benign liver nodules have refined their nosological classification. New criteria have been identified using imaging, histology and molecular a...
-
Article
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis
Hepatocellular carcinoma (HCC), the fourth leading cause of cancer mortality worldwide, develops almost exclusively in patients with chronic liver disease and advanced fibrosis1,2. Here we interrogated functions ...
-
Article
A framework for fibrolamellar carcinoma research and clinical trials
Fibrolamellar carcinoma (FLC), a rare, lethal hepatic cancer, occurs primarily in adolescents and young adults. Unlike hepatocellular carcinoma, FLC has no known association with viral, metabolic or chemical a...
-
Article
Open AccessMulti-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies. T...
-
Article
Open AccessPlk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
Polo-like kinase 1 (Plk1) expression is inversely correlated with survival advantages in many cancers. However, molecular mechanisms that underlie Plk1 expression are poorly understood. Here, we uncover a hypo...
-
Article
Hepatocellular carcinoma
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. I...
-
Article
The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma
The oncofetal long noncoding RNA (lncRNA) H19 is postnatally repressed in most tissues, and re-expressed in many cancers, including hepatocellular carcinoma (HCC). The role of H19 in carcinogenesis is a subject o...
-
Article
The role of telomeres and telomerase in cirrhosis and liver cancer
Telomerase is a key enzyme for cell survival that prevents telomere shortening and the subsequent cellular senescence that is observed after many rounds of cell division. In contrast, inactivation of telomeras...
-
Article
Open AccessDissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three maj...
-
Article
Open AccessCyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress
Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. Here, we identify a hepatocellular carcinoma (HCC) subgroup exhibiting cyclin activation through various mechanisms includi...
-
Article
Open AccessThe clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma
Efforts have been made to classify Hepatocellular Carcinoma (HCC) at surgically curable stages because molecular classification, which is prognostically informative, can accurately identify patients in need of...
-
Article
Open AccessMutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis
Genomic alterations driving tumorigenesis result from the interaction of environmental exposures and endogenous cellular processes. With a diversity of risk factors, liver cancer is an ideal model to study the...
-
Article
A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
In Trp53-mutated hepatocellular carcinoma, conformation-changing aurora kinase A inhibitors disrupt aurora kinase A–MYC interactions, resulting in MYC degradation and suppression of tumor growth.
-
Article
Hepatocellular carcinoma
Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma (HCC) represents approximately 90% of all c...
-
Chapter
Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes
The main risk factors of HCC (infections by hepatitis B or C viruses, high alcohol consumption, metabolic genetic diseases or obesity) predispose to chronic liver disease leading to cirrhosis development, a ma...
